Research
Hormonal
Pharmacological inhibition of central sympathetic outflow using imidazoline I1 agonists (e.g., moxonidine) improves metabolic parameters including blood pressure, weight, and insulin sensitivity in MetS patients.
For MetS patients with hypertension, moxonidine (an imidazoline I1 agonist) may offer additional metabolic benefits like weight loss and improved insulin sensitivity, in addition to blood pressure reduction. However, long-term efficacy needs more study.
ModerateSupportsMEDIUM confidence
Moxonidine is also shown to exert beneficial effects on a diverse range of metabolic parameters including improvements in indices of glycaemic control, insulin sensitivity, dyslipidemia, and inflammation.
Why this rating
Based on a single 6-month uncontrolled observational study; larger studies needed.
Source
Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome
Alicia A. Thorp et al. · Journal of Diabetes Research · 2015
DOI 10.1155/2015/341583
narrative_reviewCited 418×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic sympathetic nervous system overactivity is a primary driver of metabolic syndrome components, including central obesity and insulin resistance, rather than merely a consequence.Good
- Lifestyle interventions, specifically weight loss and exercise, reduce sympathetic nerve activity and improve metabolic control in patients with Metabolic Syndrome.Good
- Catheter-based renal denervation reduces sympathetic nerve activity and improves glucose metabolism in patients with resistant hypertension, polycystic ovary syndrome, and obstructive sleep apnea.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →